60人以äžã®ç§åŠè ãšå»åž«ããã³ããã¯ã¯ãã³ã«ã¯è¡æ¶²ã«å¥åŠã§å±éºãªå€åããããããææ¯ç©è³ªããå«ãŸããŠããããšã確èª
å èšäºã¯ãã¡ããã/Click here to read the original article.
ãã€ãã®Covidã¯ã¯ãã³åæã¯ãŒãã³ã°ã°ã«ãŒãã¯ããäºåçç¥èŠã®èŠçŽããäžè¬ã«å ¬éãããåºç¯ãªå ±åæžã®äžã§ãã°ã«ãŒãã¯åæãããã¹ãŠã®ã³ãããã¯ã¯ãã³ããµã³ãã«ããæ€åºãããæå®³ç©è³ªãšãã¯ã¯ãã³æ¥çš®è ããæ¡åããè¡æ¶²ãµã³ãã«ã«èŠãããèããå€åã«ã€ããŠè¿°ã¹ãŠããŸãã ãŸããè質ããç²åã®ãšã³ãããŒãã®å®å®æ§ãé«ããã°é«ãã»ã©ãã¯ã¯ãã³ã®å¯äœçšãããé »ç¹ã«çºçããããšãæããã«ããã
ã人åœãšå ¬å ±ã®å®å šã«å¯ŸããçŽæ¥çã§å·®ãè¿«ã£ãå±éºãåé¿ããããã«ãã³ããã19ã®ã¯ã¯ãã³æ¥çš®ããã°ã©ã ãçŽã¡ã«äžæ¢ãããããé¡ãããŸãããšãåã°ã«ãŒãã®å ±åæžã¯è¿°ã¹ãŠããã
ã³ãããã¯ã¯ãã³åæã¯ãŒãã³ã°ã°ã«ãŒãã¯ãæ°åã³ããã19 ãã¯ã¯ãã³ ãã®å 容ãšå¹æãåæããäœæ¥ãåŒãåããåŠéçãªã¯ãŒãã³ã°ã°ã«ãŒãã§ãããã®ã°ã«ãŒãã¯ã60人以äžã®å»åž«ãå»åž«ãè¬å€åž«ãç§åŠè ãæ°åŠè ã代æ¿å»çåŸäºè ãåŒè·å£«ããžã£ãŒããªã¹ããããªãã³ã¢ããŒã ãæã¡ãåœéçã«ãããã¯ãŒã¯åãããã¯ãŒãã³ã°ã°ã«ãŒãã§ããã
åã°ã«ãŒãã¯ã2020幎3æä»¥éãåäŸã®ãªãæ¿æ²»ç¶æ³ã«é¥ã£ããããå ±åæžã®å 容ã¯éäŸã®ãã¢ã¬ãã¥ãŒã»ããã»ã¹ãçµãŠããªãããšãææããããããããç§ãã¡ã®åœéçãªãããã¯ãŒã¯ã®äžã§ãäœäººãã®é«ãèœåãæã€ååããç§ãã¡ã®çºè¡šãæ¹å€çã«èŠãŠããã£ãŒãããã¯ããŠãããŸãããã ãšè¿°ã¹ãŠããŸãã
ãã®èŠçŽã¯ãããããã³ãã19ã¯ã¯ãã³ã«é¢ããæã ã®ç ç©¶ãšç¥èŠãããã³æã ãçºèŠãã人äœããã³ç¹ã«è¡æ¶²ãžã®åœ±é¿ã«ã€ããŠãäºåçãã€ç¶ç¶çã«çºè¡šãããã®ã§ããããã®èŠçŽã¯ãå ¬å ±ã®å©çãšãããªãç§åŠçè°è«ãä¿é²ããããšãç®çãšããŠããŸãã
ã³ãããã¯ã¯ãã³åæã¯ãŒãã³ã°ã°ã«ãŒãã¯ãåæ§ã®èª¿æ»ã宿œããç§ãã¡ã®èª¿æ»ãšäžèŽããçµæãåŸãŠããããã€ãã®åœéã°ã«ãŒããšå¯æ¥ãªååé¢ä¿ãä¿ã¡ãªããæŽ»åãç¶ããŠããŸãããã®çµæãç§ãã¡ã®ã¯ã¯ãã³åæçµæã¯ãçžäºæ€èšŒããããã®ãšã¿ãªãããšãã§ããŸãã
ã¯ã¯ãã³ã¡ãŒã«ãŒãšããã€ãã§ã¯Paul Ehrlich InstituteïŒãã€ãé£éŠä¿å¥çã®ã¯ã¯ãã³èŠå¶æ åœæ©é¢ïŒãæºè¶³ã®ããçããåºãå¿ èŠãããçåããããŸããã¯ã¯ãã³ãšæ»äº¡äºæ ãšã®å æé¢ä¿ã調æ»ããå¿ èŠãããã
è¡æ¶²ãµã³ãã«ã®æ€æ»
åœã°ã«ãŒãã¯ã48人ã®ã¯ã¯ãã³æ¥çš®è ã®è¡æ¶²ãµã³ãã«ã調æ»ããŸããã
ã¯ã¯ãã³æªæ¥çš®è ãšã¯ã¯ãã³æ¥çš®è ã®è¡æ¶²ãµã³ãã«ãæèŠéé¡åŸ®é¡ã§æ¯èŒãããšãããã³ããã19ã¯ã¯ãã³ãæ¥çš®ãã人ã®è¡æ¶²ã«ã¯ãããããé¡èãªå€åãèŠããããããã¯ãããšããã®æç¹ã§ã¯ã¯ã¯ãã³æ¥çš®ã«å¯ŸããŠç®ã«èŠããåå¿ã瀺ããŠããªãã£ããšããŠããæããã§ãã£ããã¯ã¯ãã³ãšåããããªè€éãªæ§é ããã¯ã¯ãã³æ¥çš®è ã®è¡æ¶²ãµã³ãã«ã«èŠãããã®ã ã人工ç¥èœïŒAIïŒãçšããç»åè§£æã«ãããã¯ã¯ãã³æ¥çš®è ãšéæ¥çš®è ã®è¡æ¶²ã®éãã確èªããã
ã¯ã¯ãã³æ¥çš®è ãšéæ¥çš®è ã®äž¡æ¹ããæ¡åããå°éã®çããè¡æ¶²åæãµã³ãã«ãçšããŠã人工ç¥èœïŒAIïŒãã¯ã¯ãã³æ¥çš®è ãšéæ¥çš®è ã®è¡æ¶²ã100%ã®ä¿¡é ŒåºŠã§åºå¥ã§ããããšãçªãæ¢ããŸããããã®ããšã¯ãã³ãã19ã®ã¯ã¯ãã³ã¯ãæ¥çš®ãã人ã®è¡æ¶²ã®çµæããæ¬äººãæèããããšãªãé·æçã«å€åãããããšãã§ããããšã瀺ããŠããã
ã¯ã¯ãã³æ¥çš®ãåãã人ããæ¡åããè¡æ¶²ãµã³ãã«ã®å šãŠã«ãçµæ¶ã®ãããªãã®ãèŠã€ãããŸãããèè ãã¯ããæã ã¯ããããã®åœ¢æç©ã®åæãç¶ããŠããããšè¿°ã¹ãŠããã ã°ã«ãŒãã¯ãŸãããã¹ãŠã®ã¯ã¯ãã³æ¥çš®ããããµã³ãã«ã§èµ€è¡çã®ã«ãŒããŒã®åœ¢æã芳å¯ãããã¯ã¯ãã³æ¥çš®ãããè¡æ¶²äžã®ç°ãªãã¿ã€ãã®çްèã®ç°åžžã«éã厩å£ãé »ç¹ã«èгå¯ãããããšè¿°ã¹ãã
以äžã¯ãå ±åæžã«å«ãŸãã倿°ã®ç»åã®äžéšã§ãããç»åã®èª¬æã¯èªæã§ããã


ã¯ã¯ãã³ç¶ã®å 容ç©ã®åæ

äžã®æåã®ãããªã§ã¯ããã¡ã€ã¹ã®Axiolabé¡åŸ®é¡ã䜿ã£ãŠãComirnatyïŒãã¡ã€ã¶ãŒ-ãã€ãªNTechïŒã¯ã¯ãã³ã®ããŸããŸãªãããã調ã¹ãŠããŸãããããªã®æåŸã«ã¯ãã¯ã¯ãã³æ¥çš®ãåãã人ãã¡ã®è¡æ¶²ãµã³ãã«ãããã€ã瀺ãããŠããŸããã¯ã¯ãã³ã®ãã€ã¢ã«ã«èŠããããã®ãšé¡äŒŒããæ§é ããè¡æ¶²ãµã³ãã«ã«ãèŠãããŸããã
2ã€ç®ã®ãããªã§ã¯ãæ¯èŒã®ããã«ã2ã€ã®ã€ã³ãã«ãšã³ã¶ã¯ã¯ãã³ãæ€èšŒããŸããããã¡ã€ã¶ãŒç€Ÿã®ã³ããããã¯ã¯ãã³ããšæ¯èŒãããšããã®éããããããããŸãã
Pfizer-BioNTechãModernaãAstraZenecaã®ã¯ã¯ãã³ã®ãã€ã¢ã«ããèµ°æ»åé»åé¡åŸ®é¡ïŒä»¥äžãSEMïŒããã³ãšãã«ã®ãŒåæ£åXç·åå æ³ïŒä»¥äžãEDXïŒã§èª¿æ»ããŸããã æ€åºãããäž»ãªéå±å çŽ ã¯ä»¥äžã®éãã§ãã

èè ãã¯ããžã§ã³ãœã³ã»ãšã³ãã»ãžã§ã³ãœã³ïŒã€ã³ã»ã³ïŒãã«ãã«ããã¯ã¹ãã€ã³ãã©ã¹ãããã»ããã©ã®ã¯ã¯ãã³ã®å 容ç©ãSEMãšEDXãçšããŠåæèª¿æ»ããçµæãä»ã®ãšãããã®çš®ã®æ±æãç²åã®å åã¯èŠãããªããšè¿°ã¹ãŠããã
ãã®å¹æã«èå³ãæã€äººã®ããã«ãå ±åæžã®19ããŒãžãã21ããŒãžã«ãããŠãèè ã¯äžèšã®ãªã¹ãã«åŸã£ãŠãèŠã€ãã£ãåå çŽ ã®ç°¡åãªå»åŠç衚瀺ãæäŸããŠããŸãã äŸãã°ãèè ã¯æ¬¡ã®ããã«ä»®èª¬ãç«ãŠãŠããã
ãå»åŠçèŠå°ãããã»ã·ãŠã ã¯æ²»çç䟡å€ããªããããã©ããããã»ã·ãŠã ã®æ·»å ã¯ã«ãªãŠã ã®ãã©ã³ã¹ãä¹±ããã¯ã¯ãã³æ¥çš®ã®å¹æãããããå éããããããããã¯ãã®å¹æãå±ããããªãããã«éèŠãªçްèïŒäŸãã°ãé²è¡çްèïŒãæ»ãªããæãããããšæ³å®ããªããã°ãªããªãã ãããã
ããã«ãèªå°çµåãã©ãºã(以äžãICP)ã䜿çšããŠãModernaãšPfizer-BioNTechã®ã¯ã¯ãã³ãã€ã¢ã«å 容ç©ã調æ»ããŸãããèè ãã¯ããµã³ãã«ç©è³ªãå°éãããªããããä»åã®çµæã¯ä»ã®ã°ã«ãŒãã«ãã£ãŠæ€èšŒãããå¿ èŠããããšè¿°ã¹ãŠããŸãã ããããã¢ãã瀟ã®ãµã³ãã«ããã¯ã¢ã³ãã¢ã³ãæ€åºãããã
ã¢ã³ãã¢ã³ïŒSbïŒã¯å€©ç¶ã«ååšããå çŽ ã§ãæ¯æ§ã®é«ãéå±ãšå®çŸ©ãããŠãããå ±åæžã®èè ã¯ã¢ã³ãã¢ã³ã®ææ©éå±ååç©ãæåè«ïŒæå¯çè«å¹æãæãããšè¿°ã¹ãŠãããäŸãã°5䟡ã®ã¢ã³ãã¢ã³ïŒã¹ãã[V]-ã°ã«ã³ã³é žãããªãŠã ïŒã¯ç±åž¯ã®å¯çè«çã§ãããªãŒã·ã¥ããã¢çã®æ²»çã«äœ¿çšãããŠããŸãããŸããã¢ã³ãã¢ã³ã¯ãããŸã§ã®ã¯ã¯ãã³ã®æåè«ã¢ãžã¥ãã³ããšããŠèŠåºãããŠããŸããååŠç䟡æ°ã«ãã£ãŠæ¯æ§ã«éãããããŸããããææãšããŠå¿çšã§ããé žåã¢ã³ãã¢ã³ã¯5䟡ã§ååšããŸãã
çŸåšåŸãããŠããçµæã§ã¯ãïŒã¢ããã®Covidã¯ã¯ãã³ã®ãµã³ãã«ã«å«ãŸããïŒçšéã¯æ¯æ§ã§ã¯ãªãã£ããæ€æ»ãããã¢ãã瀟補ã¯ã¯ãã³ã«å«ãŸããã¢ã³ãã¢ã³ãã©ã®äŸ¡æ°ã§ååšãããã¯ãŸã æããã§ã¯ãªããäžè¬ã«ã¯ã¯ãã³äžã®ã¢ã³ãã¢ã³ã®åºçŸã«é¢ããå ¬åŒæ å ±ã¯ä»ã®ãšããå ¬è¡šãããŠããªãã
ã¢ã³ãã¢ã³ã¯ããç²åã®åœ¢ã§é žåã¢ã³ãã¢ã³ãšããŠäœ¿çšããããšãã§ããŸããããããã¢ããã§ã®ããç²åã®æ§é ã«é¢ããå ¬åŒæ å ±ã¯ãmRNAã³ãŒãã£ã³ã°ã®ãªããœãŒã æ§é ãææããŠããŸããã¢ã³ãã¢ã³ã«ã€ããŠã¯èšåãããŠããŸããã
çŸåšåŸãããŠããç¥èŠã§ã¯ãã¢ã³ãã¢ã³ãå ç«æå¶å¹æãçºæ®ãããšããä»®å®ãæ®ã£ãŠããŸãã
æ¯æ§ã«é¢ããŠã¯ãã¢ããã®äŸ¡æ°ã§æãå¯èœæ§ã®é«ã5䟡ã®ã¹ããã°ã«ã³ã³é žãããªãŠã ãçŽæ¥è¡æµã«æäžããå Žåã®å¯äœçšãšããŠãåãæ°ãååãçèçãé çãåç ãå¿é»å³å€åãé·ææäžã§ã¯èºçãè¡çé害ãèæ©èœéå®³ãæ³šæãããã¹ããšãããŠããããšã«çæããå¿ èŠããããŸããçºçããå Žåãããé節ãªé害ã¯äž»ã«èèãšå¿èã«åã³ãŸãããããã¯ãããããã¯ã¯ãã³æ¥çš®åŸã«èгå¯ãããèšåºäºè±¡ã§ãã
è質ããç²åã®å®å®æ§
mRNAã现èã«å ¥ãã«ã¯ãä¿è·èãå¿ èŠã§ãããã®ä¿è·èã¯ããèè³ªã§æ§æãããŠããŸããããè質ã¯ããªãšãã¬ã³ã°ãªã³ãŒã«ïŒãPEGãïŒã®å±€ã«ãã£ãŠå®å®åãããŠãããPEGã¯ç°ãªãé·ãã®éã§åœ¢æãããŠãããmRNAãä¿è·ããããè質ç²åã®æ§é ã以äžã«æš¡åŒçã«ç€ºãã

以äžã¯ãæ¬ é¥ã®ããè質ããç²åã®æš¡åŒå³ã§ããã

è質ããç²åã®ãšã³ãããŒãã®å®å®æ§ã¯ãã¯ã¯ãã³ã®å¯äœçšãå·å®³ã®çºççãšå¯æ¥ã«é¢é£ããŠããããã®ãšã³ãããŒããå®å®ã§ããã°ããã»ã©ã现èã«æµžéããmRNAã®éãå€ããªããããã§ã¹ãã€ã¯ã¿ã³ãã¯è³ªã®ç£çãè¡ãããã®ã§ããããããã®çµæã¯ãã¯ã¯ãã³ã«ããå·å®³ã§æ»äº¡ãã人ã ã®æ€æ»ãè¡ã£ãç çåŠè ã®æèŠãšäžèŽããŠãããã¹ãã€ã¯ã»ã¿ã³ãã¯è³ªã¯ãæå·ããçµç¹ã§æ€åºããããç ç©¶è ãã¡ã¯ãã¹ãã€ã¯ã»ãããã€ã³ãããèªäœãæ¯æ§ãæã€ã®ã§ã¯ãªãããšèããŠããŸãã
ãã®å ±åæžã®èŠæšãšãªã³ã¯ã¯ãAna Maria Mihalceaå士ã®Substack HEREïŒè±èªïŒãŸãã¯AG Impfstoffe AufklÀrung (WG Vaccines Education) Telegram channel HEREïŒãã€ãèªïŒã«æ²èŒãããŠããŸãã
